LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVS

128.14

-0.44%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVS

128.14

-0.44%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVS

128.14

-0.44%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVS

128.14

-0.44%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVS

128.14

-0.44%↓

Search

Arcutis Biotherapeutics Inc

Fechado

SetorSaúde

17.95 3.7

Visão Geral

Variação de preço das ações

24h

Atual

Mín

17.25

Máximo

18.07

Indicadores-chave

By Trading Economics

Rendimento

9.2M

-16M

Vendas

16M

82M

Margem de lucro

-19.491

Funcionários

342

EBITDA

6.7M

-12M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+27.87% upside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

130M

1.9B

Abertura anterior

14.25

Fecho anterior

17.95

Sentimento de Notícias

By Acuity

59%

41%

315 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

Arcutis Biotherapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

9 de set. de 2025, 23:37 UTC

Ações em Alta

Stocks to Watch: Oracle, Wearable Devices, GameStop

9 de set. de 2025, 20:41 UTC

Ganhos

Oracle's Backlog Surges With Major Customer Deals in 1Q

9 de set. de 2025, 20:30 UTC

Ganhos

GameStop 2Q Sales, Profit Rise

9 de set. de 2025, 23:19 UTC

Conversa de Mercado

ANZ Adds a Further 50 Bps in FOMC Cuts to Outlook -- Market Talk

9 de set. de 2025, 21:35 UTC

Ganhos

Oracle Stock Soars on Strong AI Backlog. Earnings Were Good Enough. -- Barrons.com

9 de set. de 2025, 21:32 UTC

Ganhos

Oracle's Backlog Swells With Big Customer Deals -- Update

9 de set. de 2025, 21:02 UTC

Aquisições, Fusões, Aquisições de Empresas

DHL Adds to Healthcare Logistics Services With Acquisition -- Update

9 de set. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

9 de set. de 2025, 20:33 UTC

Ganhos

These Stocks Moved the Most Today: Apple, UnitedHealth, Nebius, Wolfspeed, Tourmaline Bio, Albemarle, Dell, and More -- Barrons.com

9 de set. de 2025, 20:26 UTC

Ganhos

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 de set. de 2025, 20:23 UTC

Ganhos

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 de set. de 2025, 20:12 UTC

Ganhos

Oracle Stock Jumps on Mixed Earnings Report -- Barrons.com

9 de set. de 2025, 20:10 UTC

Ganhos

Oracle Expects Cloud Infrastructure Rev to Grow 77% to $18 B This Fiscal Yr >ORCL

9 de set. de 2025, 20:10 UTC

Ganhos

Oracle Expects to Sign-Up Several Additional Multi-B-dollar Customers and RPO Is Likely to Exceed Half-A-Trillion Dollars Over Next Few Mos

9 de set. de 2025, 20:09 UTC

Ganhos

Synopsys Sees 4Q Adj EPS $2.76-Adj EPS $2.80 >SNPS

9 de set. de 2025, 20:09 UTC

Ganhos

Synopsys Sees 4Q Loss/Shr 16c-Loss 27c >SNPS

9 de set. de 2025, 20:08 UTC

Ganhos

Oracle 1Q Short-term Deferred Rev Were $12.1 B >ORCL

9 de set. de 2025, 20:08 UTC

Ganhos

Oracle 1Q Operating Income Was $4.3 B >ORCL

9 de set. de 2025, 20:08 UTC

Ganhos

Oracle Expects MultiCloud Rev to Grow Substantially Every Qtr for Several Years >ORCL

9 de set. de 2025, 20:08 UTC

Ganhos

Synopsys Sees 4Q Rev $2.23B-$2.26B >SNPS

9 de set. de 2025, 20:07 UTC

Ganhos

Oracle Total Remaining Performance Obligations Up to $455 B >ORCL

9 de set. de 2025, 20:06 UTC

Ganhos

Oracle 1Q Software Revenue $5.72B >ORCL

9 de set. de 2025, 20:06 UTC

Ganhos

Synopsys 3Q Adj EPS $3.39 >SNPS

9 de set. de 2025, 20:06 UTC

Ganhos

Oracle 1Q Cloud Revenue $7.19B >ORCL

9 de set. de 2025, 20:05 UTC

Ganhos

Oracle 1Q Rev $14.93B >ORCL

9 de set. de 2025, 20:05 UTC

Ganhos

Oracle 1Q EPS $1.01 >ORCL

9 de set. de 2025, 20:05 UTC

Ganhos

Synopsys 3Q EPS $1.50 >SNPS

9 de set. de 2025, 20:05 UTC

Ganhos

Oracle 1Q Services Revenue $1.35B >ORCL

9 de set. de 2025, 20:05 UTC

Ganhos

Oracle 1Q Adj EPS $1.47 >ORCL

9 de set. de 2025, 20:05 UTC

Ganhos

Oracle 1Q Hardware Revenue $670M >ORCL

Comparação entre Pares

Variação de preço

Arcutis Biotherapeutics Inc Previsão

Preço-alvo

By TipRanks

27.87% parte superior

Previsão para 12 meses

Média 22.16 USD  27.87%

Máximo 29 USD

Mínimo 14.29 USD

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Arcutis Biotherapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

8 ratings

7

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

12.42 / 14.93Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bullish Evidence

Sentimento

By Acuity

315 / 371 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
help-icon Live chat